Altamira Therapeutics Ltd. (CYTO) shares have gained 38.64% at $0.96 in early Friday’s session. Altamira Therapeutics (CYTO) stock finished the last trading session at $0.69. The stock recorded a trading volume of 0.58 million shares, which is below the average daily trading volume published for the last 50 days of 0.29 million shares.
The shares of Altamira Therapeutics (CYTO) have retreated -24.04% in the last five days; however, they have lost -47.24% over the last month. The stock price has shed -56.25% over the last three months and has lost -61.92 percent so far this year. CYTO stock is gaining traction after announcing encouraging results of its nasal spray.
Which CYTO drug showed accomplishment against which infection?
Altamira Therapeutics (CYTO) is devoted to creating therapeutics that address significant neglected clinical necessities. CYTO is presently dynamic in three regions:
- Advancement of RNA therapeutics for extrahepatic restorative targets (OligoPhore/SemaPhore stages; preclinical).
- Nasal spray for assurance against airborne infections and allergens (Bentrio; business) or for the treatment of dizziness (AM-125; Phase 2).
- The improvement of therapeutics for the intratympanic treatment of tinnitus or hearing misfortune (Keyzilen and Sonsuvi; Phase 3).
Altamira Therapeutics (CYTO) today declared positive adequacy information from testing its Bentrio nasal spray in vitro against the Omicron variation of the SARS-CoV-2 infection.
- Bentrio, a medication-free nasal spray proven to protect against airborne infections and allergens, has recently shown positive results in vitro against the first SARS-CoV-2 infection and its Delta variant.
- As in the past investigations, reconstituted nasal epithelium cells from human donors were employed for the Omicron variation study, which used either Bentrio or saline controls.
- When compared to the Delta variation, the Omicron variation displayed much faster popular replication and a much faster expansion of the viral titer in tissue cultures (as measured by the Median Tissue Culture Infectious Dose, TCID50), which had topped within 24 hours.
- In contrast to saline-treated controls, prophylactic Bentrio uses beginning 10 minutes before the viral vaccination caused an 89.5% reduction in viral titers within 24 hours (p-value<0.01).
- At the point when the treatment application was begun just a brief time after viral vaccination after the viral titer had effectively topped, use of Bentrio brought about a huge decrease in viral titer throughout the next days (generally p<0.01) contrasted with saline controls, coming to 87.1% at its most extreme on Day 3.
How these results will impact CYTO?
Altamira Therapeutics (CYTO) has added to the evidence suggesting Bentrio may protect against SARS-CoV-2. The study supports Bentrio’s effectiveness across a range of virus strains, suggesting that it is applicable to a wide range of infections. These results reinforced CYTO’s belief in Bentrio’s compatibility with both highly contagious Delta and Omicron variants.
